Palliative Lattice Stereotactic Body Radiotherapy (SBRT) for Patients With Sarcoma, Thoracic, Abdominal, and Pelvic Cancers

Recruiting in Palo Alto (17 mi)

Overseen byPamela Samson, M.D.

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Washington University School of Medicine

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a study evaluating the safety and efficacy of Lattice SBRT for patients with large tumors (≥ 4.5 cm) planning to undergo palliative radiotherapy.

Eligibility Criteria

Inclusion Criteria

Histologically or cytologically confirmed sarcoma (including extremity), thoracic cancer (including esophageal), abdominal cancer (including retroperitoneal sarcoma), or pelvic cancer.

Planning to undergo palliative radiotherapy to a lesion ≥ 4.5 cm as measured with radiographic imaging or with calipers by clinical exam.

ECOG performance status ≤ 2

See 3 more

Exclusion Criteria

Pregnant. Women of childbearing potential must have a negative pregnancy test within 20 days of study entry.

You may have had or plan to have chemotherapy or VEGF inhibitors before or after the radiotherapy, based on the decision of your radiation oncologist. You can continue your ongoing treatment plan during the radiotherapy. It is recommended, but not mandatory, to wait two weeks before starting radiotherapy after taking these drugs.

Prior high-dose radiotherapy that overlaps with any planned site of protocol radiotherapy. Patients where the Lattice SBRT fields may overlap with the low dose (<10 Gy) region of prior radiotherapy treatments are eligible and may be treated if this is determined to be safe by the treating physician.

See 3 more